1 vote

Repurposing of Meropenem and Nadifloxacin for Treatment of Burn Patients?

Joseph G. Moloughney¹, Janice D. Thomas¹, Christie E. Costa², Karla S. Bullon², James Spencer³ & Jeffrey H. Toney⁴

Correspondence: (Login to view email address)

1. Pharmacology, University of Medicine and Dentistry of New Jersey
2. Biological Sciences, Kean University
3. Cellular and Molecular Medicine, University of Bristol
4. College of Natural, Applied and Health Sciences, Kean University

PDF (124.2 KB)

Document Type:

Manuscript

Date:

Received 14 September 2009 20:46 UTC; Posted 15 September 2009

Subjects:

Pharmacology

Tags:

• drug development
• repurposing
• antibiotic resistance

Abstract:

The escalating number of multidrug resistant pathogens has demanded the swift development of new and potent antibiotics (ref. 2). Metallo-β-lactamases (MBLs) continue to evolve, rendering the latest generation of carbapenem antibiotics useless (ref. 8). SPM-1, a recently discovered MBL, was isolated from a juvenile leukemia patient residing in a hospital in San Palo, Brazil just prior to the patient succumbing to septicemia brought on by Pseudomonas aeruginosa expressing SPM-1 (ref. 8). Screening of the Johns Hopkins Compound library of 1,514 FDA or FAD approved drugs (ref. 1) identified a novel SPM-1 inhibitor that is synergistically compatible with meropenem. Using clinically achievable concentrations, meropenem coupled with nadifloxacin inhibits Pseudomonas aeruginosa expressing SPM-1. This shotgun approach to new drug discovery provided a prompt solution to the grave problem of antibiotic resistant pathogens that are thriving in hospitals today.

Discussion

Votes:

1 vote

(Login to vote)

Comments:

0 comments

(Login to post a comment)

Share:

(Login to share with a colleague)

Additional information

License:

This document is licensed to the public under the Creative Commons Attribution 3.0 License

How to cite this document:

Moloughney, Joseph, Thomas, Janice, Costa, Christie, Bullon, Karla, Spencer, James, and Toney, Jeffrey. Repurposing of Meropenem and Nadifloxacin for Treatment of Burn Patients?. Available from Nature Precedings <http://hdl.handle.net/10101/npre.2009.3761.1> (2009)

Version info:

Other versions of this document in Nature Precedings

None.

Other versions of this document elsewhere on the web

None known.

Submit a new version link